

Table SI. Number of patients prescribed each of the various first line treatments.

Year	2011 (%)	2012 (%)	2013 (%)	2014 (%)	2015 (%)
Platinum-based compounds , n (%)	4,091 (47.75)	3,631 (42.69)	3,043 (41.70)	3,743 (40.39)	3,061 (39.91)
TCC	61 (0.71)	56 (0.66)	35 (0.48)	53 (0.57)	28 (0.37)
Monotherapy	479 (5.59)	471 (5.54)	438 (6.00)	489 (5.28)	395 (5.15)
Target therapy	1,799 (21.00)	2,391 (28.11)	2,176 (29.82)	2,978 (32.13)	2,491 (32.48)
Others	2,137 (24.94)	1,957 (23.01)	1,606 (22.01)	2,006 (21.64)	1,695 (22.10)
Total	8,567 (100.00)	8,506 (100.00)	7,298 (100.00)	9,269 (100.00)	7,670 (100.00)

Table SII. Median survival of patients treated with the various first-line treatments.

Variable	Total	Live	Dead	Median survival, months (95% CI)
Stage 1 and 2				
OP only	4,161	3,860	301	-
Chemo + OP	3,882	2,937	945	-
Platinum-based	619	242	377	20.13 (17.07-22.20)
TCC	19	19		8.57 (5.37-13.73)
Monotherapy	99	50	49	29.87 (24.03-38.80)
EGFR-TKIs	269	117	152	26.23 (22.30-31.30)
Others	662	161	501	13.8 (11.73-15.20)
Stage 3				
OP only	268	188	80	-
Chemo + OP	1,548	906	642	44.83 (39.33-48.53)
Platinum-based	2,747	719	2,028	15.47 (14.77-16.03)
TCC	42	6	36	12.6 (8.80-15.97)
Monotherapy	141	26	115	11.73 (9.27-15.20)
EGFR-TKIs	612	289	323	30.33 (26.30-34.30)
Others	1,195	140	1,055	8.40 (7.57-9.07)
Stage 4				
OP only	210	40	170	3.48 (2.67-4.70)
Chemo + OP	1,707	515	1,192	17.87 (16.77-18.93)
Platinum-based	6,989	1,077	5,912	11.0 (10.70-11.33)
TCC	117	9	108	6.6 (5.233-8.27)
Monotherapy	504	69	435	8.67 (7.17-10.03)
EGFR-TKIs	6,972	2,151	4,821	19.17 (18.70-19.67)
Others	3,965	195	3,770	3.77 (3.60-3.97)
Stage 3B and 4				
Chemo + OP	2,151	735	1,416	19.44 (18.12-21.12)
Platinum-based	8,703	1,505	7,198	11.40 (11.16-11.76)
Gefitinib	5,638	1,515	4,123	19.44 (18.84-19.92)
Erlotinib	1,433	596	837	17.52 (16.32-18.60)
Afatinib	367	258	109	-

Table SIII. Survival statistics of patients treated with the various first-line treatments.

Variable	Hazard ratio	95% CI	P-value
Stage 1 and 2			
Reference, OP only			
Chemo + OP	3.37	2.96-3.84	<0.0001 ^b
Platinum-based	14.67	12.60-17.08	<0.0001 ^b
TCC	43.03	26.34-70.27	<0.0001 ^b
Monotherapy	10.04	7.40-13.62	<0.0001 ^b
EGFR-TKIs	11.13	9.16-13.53	<0.0001 ^b
Others	20.57	17.81-23.74	<0.0001 ^b
Reference, EGFR-TKIs			
Chemo + OP	0.30	0.26-0.36	<0.0001 ^b
Platinum-based	1.317	1.09-1.59	0.0041 ^b
TCC	3.859	2.34-6.38	<0.0001 ^b
Monotherapy	0.90	0.65-1.25	0.53
OP only	0.09	0.07-0.11	<0.0001 ^b
Others	1.85	1.54-2.21	<0.0001 ^b
Stage 3			
Reference, OP only			
Chemo + OP	1.34	1.06-1.69	0.0134 ^a
Platinum-based	3.56	2.85-4.46	<0.0001 ^b
TCC	5.43	3.66-8.05	<0.0001 ^b
Monotherapy	4.29	3.23-5.71	<0.0001 ^b
EGFR-TKIs	1.96	1.53-2.50	<0.0001 ^b
Others	6.59	5.25-8.28	<0.0001 ^b
Reference, EGFR TKIs			
Chemo + OP	0.68	0.60-0.78	<0.0001 ^b
Platinum-based	1.82	1.62-2.04	0.0041 ^b
TCC	2.77	1.96-3.91	<0.0001 ^b
Monotherapy	2.19	1.77-2.71	0.53
OP only	0.51	0.40-0.65	<0.0001 ^b
Others	3.36	2.97-3.81	<0.0001 ^b
Stage 4			
Reference OP only			
Chemo + OP	0.44	0.38-0.52	<0.0001 ^b
Platinum-based	0.70	0.60-0.82	<0.0001 ^b
TCC	1.11	0.87-1.41	0.41
Monotherapy	0.83	0.69-0.99	0.036 ^a
EGFR-TKIs	0.44	0.38-0.52	<0.0001 ^b
Others	1.54	1.32-1.79	<0.0001 ^b
Reference, EGFR TKIs			
Chemo + OP	0.99	0.93-1.06	0.8077
Platinum-based	1.58	1.53-1.65	<0.0001 ^b
TCC	2.50	2.07-3.02	<0.0001 ^b
Monotherapy	1.87	1.69-2.06	<0.0001 ^b
OP only	2.26	1.94-2.63	<0.0001 ^b
Others	3.47	3.32-3.62	<0.0001 ^b
Stage 3B and 4			
Reference, Chemo + OP			
Platinum-based	1.73	1.63-1.83	<0.0001 ^b
Gefitinib	1.11	1.04-1.18	0.0009 ^b
Erlotinib	1.21	1.11-1.32	<0.0001 ^b
Afatinib	0.66	0.55-0.81	<0.0001 ^b
Reference, Gefitinib			
Platinum-based	1.56	1.50-1.62	<0.0001 ^b
Chemo+OP	0.90	0.85-0.96	0.0009 ^b
Erlotinib	1.10	1.02-1.18	0.0171 ^a
Afatinib	0.60	0.50-0.73	<0.0001 ^b

^aP<0.05, ^bP<0.001. Op, operation; TCC, paclitaxel, vinorelbine, gemcitabine and docetaxel; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.

Table SIV. Median survival of patients treated with the various first-line treatments based on EGFR mutation status.

Variable	Total	Live	Dead	Median survival, months (95% CI)
EGFR mutation (+)				
Chemo-Op	854	378	476	27.33 (24.9-29.73)
Platinum-Based	744	188	556	20.7 (18.57-21.53)
EGFR-TKIs	6,504	2,213	4,291	20.3 (19.7-20.83)
EGFR (-)				
Chemo-Op	613	175	438	15.97 (14.03-17.47)
Platinum-Based	2,956	657	2,299	12.53 (11.93-13.1)
EGFR-TKIs	291	45	246	10.47 (8.0-12.53)
EGFR (unknown)				
Chemo-Op	684	182	502	15.3 (13.67-17.1)
Platinum-Based	5,003	660	4,343	10.4 (10.13-10.77)
EGFR-TKIs	643	111	532	15.83 (14.43-17.53)

Table SV. Survival statistics of patients treated with the various first-line treatments based on EGFR mutation status.

Variable	Hazard ratio	95% CI	P-value
EGFR Mutation (+)			
Reference, platinum-based compounds			
Chemo + OP	0.70	0.62-0.79	<0.0001 ^b
EGFR-TKIs	1.01	0.93-1.10	0.82
Reference, EGFR-TKIs			
Chemo + OP	0.69	0.63-0.76	<0.0001 ^b
Platinum-Based	0.99	0.91-1.08	0.82
EGFR Mutation (-)			
Reference, platinum-based compounds			
Chemo + OP	0.80	0.72-0.88	<0.0001 ^b
EGFR-TKIs	1.19	1.05-1.36	0.008 ^a
Reference, EGFR-TKIs			
Chemo + OP	0.67	0.57-78	<0.0001 ^b
Platinum-Based	0.84	0.73-0.96	0.008 ^a
EGFR Mutation (unknown)			
Reference, platinum-based compounds			
Chemo + OP	0.62	0.56-0.68	<0.0001 ^b
EGFR-TKIs	0.75	0.68-0.82	<0.0001 ^b
Reference, EGFR-TKIs			
Chemo + OP	0.83	0.73-0.94	0.003 ^a
Platinum-Based	1.34	1.22-1.46	<0.0001 ^b

^aP<0.01, ^bP<0.001. Op, operation; TCC, paclitaxel, vinorelbine, gemcitabine and docetaxel; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.

Table SVI. Median survival of patients treated with the various second-line treatments.

Variable	Total	Live	Dead	Median survival, months (95% CI)
Afatatinib	109	97	12	-
Docetaxel	4,427	1,223	3,204	7.9 (7.60-8.27)
Erlotinib	3,901	911	2,990	6.73 (6.37-7.23)
Gefitinib	1,230	428	802	16.23 (14.83-18.17)
Etoposide	599	142	457	6.13 (5.10-6.93)
Gemcitabin	3,298	970	2,328	8.2 (7.77-8.60)
Paclitaxel	1,669	475	1,194	7.77 (7.27-8.40)
Pemetrexed	4,962	1,820	3,142	11.73 (11.33-12.17)
Vinorelbin	4,050	1,197	2,853	7.80 (7.47-8.13)

Table SVII. Survival statistics of patients treated with the various second-line treatments.

Variable	Hazard ratio	95% CI	P-value
Reference, Gefitinib			
Afatinib	0.31	0.18-0.55	<0.0001 ^a
Docetaxel	1.82	1.68-1.97	<0.0001 ^a
Erlotinib	1.84	1.70-1.99	<0.0001 ^a
Etoposide	2.09	1.86-2.34	<0.0001 ^a
Gemcitabin	1.79	1.65-1.95	<0.0001 ^a
Paclitaxel	1.89	1.73-2.07	<0.0001 ^a
Pemetrexed	1.29	1.19-1.40	<0.0001 ^a
Vinorelbin	1.77	1.64-1.92	<0.0001 ^a
Reference, Pemetrexed			
Afatinib	0.24	0.14-0.42	<0.0001 ^a
Docetaxel	1.41	1.34-1.48	<0.0001 ^a
Erlotinib	1.42	1.35-1.50	<0.0001 ^a
Etoposide	1.62	1.46-1.78	<0.0001 ^a
Gemcitabin	1.39	1.31-1.46	<0.0001 ^a
Paclitaxel	1.46	1.37-1.56	<0.0001 ^a
Pemetrexed	0.78	0.72-0.84	<0.0001 ^a
Vinorelbin	1.37	1.31-1.45	<0.0001 ^a

^aP<0.001. CI, confidence interval.